Articles

  1. DeWitte O, Lefranc F, Salmon I, Violon P, Brotchi J. Métastases cérébrales d’origine gynécologique. Neurochirurgie 42:216-220,1996.
  2. Lefranc F, DeWitte O, David Ph, Brotchi J. Traumatic epidural hematoma of the cervical spine : Magnetic resonance imaging diagnosis and spontaneous resolution. Neurosurgery 44 :408-411, 1999.
  3. Lemaitre J, Jamart S, Lefranc F, Julien V, Vincent JL. Fistule carotido-caverneuse post-traumatique. Rev Med Bruxelles 20 : 91-94, 1999.
  4. Brotchi J, Lefranc F. Current management of spinal cord tumors. Contemporary Neurosurg 21 :1-8, 1999.
  5. Lefranc F, DeWitte O, David Ph, Brotchi J. Hémorragie cérébelleuse compliquant une crâniotomie supra-tentorielle : un cas rapporté et revue de la littérature. Neurochirurgie 46 :395-397, 2000.
  6. Camby I, Lefranc F, Titeca G, Neuci S, Fastrez M, Dedecken L, Schäfer BW, Brotchi J, Heizmann CW, Pochet R, Salmon I, Kiss R, Decaestecker C. Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumors. Neuropathol Appl Neurol 26 :76-90, 2000.
  7. DeWitte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S. FDG-PET as a prognostic factor in high-grade astrocytoma. J Neuro-Oncol 49 :157-163, 2000.
  8. Lefranc F, Nagy N, DeWitte O, Baleriaux D, Brotchi J. Intracranial meningioma revealed by non traumatic subdural hematoma : series of four cases. Acta Neurochir 143 :977-982, 2001.
  9. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11 :12-26, 2001.
  10. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S, Maurage CA, Kaltner H, Ruchoux MM, Danguy A, Gabius HJ, Salmon I, Kiss R, Camby I. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. GLIA 33 :241-255, 2001.
  11. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, DeDecker R, Micik S, Brotchi J, Decaestecker C, Salmon I, Kiss R, Camby I. The molecular characterization of cell-substratum attachments in human glial tumors relates to prognostic features. GLIA 36 :375-390, 2001.
  12. Lefranc F, Cool V, Velu T, Brotchi J, De Witte O. Granulocyte macrophage-colony stimulating factor (GM-CSF) gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. Int J Oncol 20 :1077-1085, 2002.
  13. Lefranc F, Golzarian J, Chevalier C, De Witte O, Pochet R, Heizman C, Decaestecker C, Brotchi J, Salmon I, Kiss R. Characterization of the level of expression of S100B, S100A1, S100A2, S100A4 and S100A6 calcium-binding proteins in a rat model of cerebral basilar artery vasospasm. J Neurosurg 97 :408-415, 2002.
  14. Lefranc F, Camby I, Belot N, Bruyneel E, Mareel M, Brotchi J, Salmon I, Kiss R. Gastrin significantly modifies the migratory abilities of experimental malignant astrocytic tumors. Lab Invest 82 :1241-1252, 2002.
  15. Dereeper E, Berre J, Vandesteene A, Lefranc F, Vincent JL. Barbiturate coma for intracranial hypertension: Clinical observations. J Crit Care 17:58-62, 2002.
  16. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and the levels of expression of small GTPases. J Neuropathol Exp Neurol 61 :585-597, 2002.
  17. Branle F, Lefranc F, Camby I, Jeukens J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, Salmon I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p/19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95 :641-655, 2002.
  18. Lefranc F, Chaboteaux C, Belot N, Brotchi J, Salmon I, Kiss R. Determination of RNA expression for cholecystokinin / gastrin receptors (CCKA, CCKB and CCKC) in human tumors of the central and peripheral nervous system. Int J Oncol 22 :213-219, 2003.
  19. Lefranc F, Chevalier C, Vinchon M, Dhellemmes P, Schüring MP, Kaltner H, Brotchi J, Ruchoux MM, Gabius HJ, Salmon I, Kiss R. Characterization of the levels of expression of retinoic acid receptors (RARa, RARb, RARg), galectin-3, macrophage migration inhibitor factor (MIF) and p53 in a series of 51 adamantinomatous craniopharyngiomas. J Neurosurg 98 :145-153, 2003.
  20. Lefranc F, Sadeghi N, Metens T, Brotchi J, Salmon I, Kiss R. Characterization of gastrin-induced cytostatic effect on cell proliferation in experimental malignant gliomas. Neurosurgery 52 : 881-891, 2003.
  21. Lefranc F, Brotchi J. Surgical strategy in spinal cord hemangioblastomas. Operative Techniques in Neurosurgery 6:24-31, 2003.
  22. Lubansu A, Ruchoux MM, Brotchi J, Salmon I, Kiss R, Lefranc F. Cathepsins B, D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression. Histopathology 43 :563-572, 2003.
  23. Pelc P, Vanmuylder N, Lefranc F, Heizmann CW, Hassid S, Salmon I, Kiss R, Louryan S, Decaestecker C. Differential expression of S100 calcium-binding proteins in epidermoid cysts, branchial cysts, craniopharyngiomas and cholesteatomas. Histopathology 42 : 387-394, 2003.
  24. Sadeghi N, Rorive S, Lefranc F. Intracranial tuberculoma: is diffusion-weighted imaging useful in the diagnosis ? Eur Radiol 13:2049-2050, 2003.
  25. Lefranc F. Cerebral vasospasm: molecular analysis. Bull Mem Acad R Med Belg 158:258-264, 2003; discussion 264-266
  26. Lefranc F, Mijatovic T, Mathieu V, Rorive S, Decaestecker C, Debeir O, Brotchi J, Van Ham Ph, Salmon I, Kiss R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas, and in vitro in Human Umbilical Vein Endothelial Cells (HUVECs). Clin Cancer Res 10 :8250-8265, 2004.
  27. Pirotte B, Wikler D, David P, Lefranc F, Brotchi J, Levivier M. Magnetic resonance angiography image guidance for the microsurgical clipping of intracranial aneurysms: a report of two cases. Neurol Res 26:429-434, 2004.
  28. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis (Review). J Clin Oncol 23 :2411-2422, 2005.
  29. Lefranc F, Mijatovic T, Decaestecker C, Kaltner H, Andre S, Brotchi J, Salmon I, Gabius HJ, Kiss R. Monitoring the expression profiles of integrins and adhesion / growth regulatory galectins in adamantinomatous craniopharyngiomas: their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis. Neurosurgery 56 :763-776, 2005.
  30. Lefranc F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, Gabius HJ, Kiss R. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J Neurosurg 102 :706-714, 2005
  31. Lefranc F, Decaestecker R, Brotchi J, Heizmann CW, DeWitte O, Kiss R, Mijatovic T. Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-b, -h and –z) in a art model of cerebral basilar artery vasospasm. Neuropathol Appl Neurobiol 31:649-660, 2005.
  32. Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, Kiss R. Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 335 :27-35, 2005.
  33. Bota DP, Lefranc F, Vilallobos HR, Brimioulle S, Vincent JL. Ventriculostomy-related infections in critically ill patients : a 6-year experience. J Neurosurg 103:468-472, 2005.
  34. Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (Review). Int J Oncol 28 :1021-1030, 2006.
  35. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R. Present and potential future issues in glioblastoma treatment (Review). Expert Rev Anticancer Ther 6:719-732, 2006.
  36. Lefranc F, Kiss R. Autophagy, the Trojan horse to combat glioblastomas (Review). Neurosurg Focus 20 :e7, 2006.
  37. Ingrassia L, Nshimyumukiza P, Dewelle J, Lefranc F, Wlodarczak L, Thomas S, Dielie G, Chiron C, Zedde C, Tisnès P, van Soest R, Braeckman JC, Darro F, Kiss R. A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J Med Chem 49:1800-1807, 2006.
  38. Lubicz B, Lefranc F, Levivier M, Dewitte O, Pirotte B, Brotchi J, Baleriaux D. Endovascular treatment of intracranial aneurysms with a branch arising from the sac. AJNR Am J Neuroradiol 27:142-147, 2006.
  39. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, Ben Taib NO, Rorive S, David P, Brotchi J. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 104:238-253, 2006.
  40. Camby I, LeMercier M, Lefranc F, Kiss R. Galectin-1: A small protein with major functions (Review). Glycobiology 16 :137R-157R, 2006.
    Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, Darro F, Kiss R. Anti-galectin compounds as potential anti-cancer drugs (Review). Curr Med Chem 13:3513-3527, 2006.
  41. Lubicz B, Graca J, Levivier M, Lefranc F, Dewitte O, Pirotte B, Brotchi J, Baleriaux D. Endovascular treatment of middle cerebral artery aneurysms. Neurocrit Care 5:93-1001, 2006.
  42. Brotchi J, Bruneau M, Lefranc F, Baleriaux D. Surgery of intraspinal cord tumors. Clin Neurosurg 53 :209-216, 2006.
  43. Mégalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, Kondo Y, Kiss R, Lefranc F. 4-IBP : A sigma-1 receptor agonist decreases the migration of human cancer cells including glioblastoma cells in vitro and sensitizes them in vitro and in vivo to the cytotoxic insults of pro-apoptotic and pro-autophagic drugs. Neoplasia 9 :358-69, 2007.
  44. Lefranc F, Lubicz B, De Witte O. In vitro evidence of the role of hemoglobin during vasospasm on the modifications of the expression of PKCalpha and zeta. Int J Mol Med 20:415-419, 2007.
  45. Lefranc F, Facchini V, Kiss R. Pro-autophagic drugs : A novel means to combat apoptosis-resistant cancers. The Oncologist 12 :1395-1403, 2007.
  46. Lefranc F, Brotchi J. Performance of a new type of suction tip attachment during intramedullary tumor dissection: technical note. Neurosurgery 61:E241; 2007.
  47. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F, Kiss R. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the Death Receptor and/or the mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 9 :766-776, 2007.
  48. Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, Van Vynckt F, Mijatovic T, Lefranc F, Darro F, Kiss R. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 50 :4122-4134, 2007.
  49. Lubicz B, Baleriaux D, Lefranc F, Brotchi J, Bruneau M, Levivier M. Endovascular treatment of intracranial aneurysms as the first therapeutic option. J Neuroradiol 34 :250-259, 2007.
  50. Lefranc F, Balériaux D, Brotchi J. Intramedullary cavernomas : personal series of 24 cases. Neurochirurgie 53:203-207, 2007.
  51. Lefranc F. Les glioblastomes sont résistants à l’apoptose mais de façon moindre au processus d’autophagie. Bull Mem Acad R Med Belg 162:331-338, 2007.Lefranc F, Mijatovic T, Kondo Y, Sauvage S,
  52. Roland I, Krstic D, Vasic V, Gailly P, Kondo S, Blanco G, Kiss R.  Targeting the alpha-1 subunit of the sodium pump (the Na+/K+-ATPase) to combat glioblastoma cells. Neurosurgery 62 :211-222, 2008.
  53. Lefranc F, Mijatovic T, Kiss R. La pompe a sodium pourrait représenter une nouvelle cible pour le traitement du glioblastome. Bull Cancer 95 :271-281, 2008.
  54. Lefranc F, Kiss R. The sodium pump alpha-1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 10:198-206, 2008.
  55. Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R, Lefranc F. ORP150, a Major Target of Galectin-1 Pro-Angiogenic Effects in Human Hs683 Glioblastoma Xenografts.J Neuropathol Exp Neurol 67 :456-469, 2008.
  56. Lefranc F, Ingrassia L, Kiss R. Targeting autophagy: do patents reveal a therapeutic potential? Expert Opin Ther Patents 18:1-7, 2008.
  57. Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F. Combining Bevacizumab with temozolomide increases the anti-tumor efficacy of temozolomide in human glioblastoma orthotopic xenograft model. Neoplasia 10:1383-1392, 2008.
  58. Gnoula C, Mégalizzi V, De Neve N, Sauvage S, Ribaucour F, Guissou P, Duez P, Dubois J, Ingrassia L, Lefranc F, Kiss R, Mijatovic T. Balanitin-6 and –7 : Diosgenyl saponins isolated from Balanites aegyptiaca Del. Display significant anti-tumor activity in vitro and in vivo. Int J Oncol 32:5-15, 2008.
  59. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229:172-183, 2008.
  60. Ingrassia L, Lefranc F, Mathieu V, Darro F, Kiss R. Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising anti-tumor agents. Translational Oncology 1:1-13, 2008.
  61. Lubicz B, Collignon L, Lefranc F, Bruneau M, Brotchi J, Balériaux D, De Witte O. Circumferential and fusiform aneurysms : reconstructive endovascular treatment with self-expandable stents. Neuroradiology 50:499-507, 2008.
  62. Lubicz B, Lefranc F, Bruneau M, Balériaux D, DeWitte O. Balloon-assisted coiling of intracranial aneurysms is not associated with a higher complication rate. Neuroradiology 50:769-776, 2008.
  63. *Ingrassia L, *Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, Van Quaquebeke E, Kiss R. Structure-activity-relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae Isocarbostyril alkaloid) as potential anti-cancer agents. J Med Chem 52:1100-1114, 2009. *contributions égales
  64. Lefranc F. Editorial: On the road to multi-modal and pluri-displinary treatment of glioblastomas. Acta Neurochir (Wien) 151:109-112, 2009.
  65. Lefranc F, Rynkowski M, De Witte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg 34:3-35, 2009.
  66. Lefranc F, Sauvage S, Van Goietsenoven G, Mégalizzi V, Lamoral-Theys D, Debeir O, Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C, Kiss R. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther. 8:1739-1750, 2009.
  67. Djedid R, Kiss R, Lefranc F. Targeted therapy of glioblastomas: a 5-year review. Future Medicine 6:351-370, 2009.
  68. Lubicz B, Bruneau M, Dewindt A, Lefranc F, Balériaux D, De Witte O. Endovascular treatment of proximal anterior cerebral artery aneurysms. Neuroradiology 51:99-102, 2009.
  69. Senetta R, Trevisan E, Ruda R, Maldi E, Molinaro L, Lefranc F, Chiusa L, Lanotte M, Soffietti R, Cassoni P. Caveolin-1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol 68:425-431, 2009.
  70. Ingrassia L, Lefranc F, Kiss R, Mijatovic T. Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 16:1192-1213, 2009.
  71. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R. Galectin-1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 11:485-496, 2009.
  72. Mégalizzi V, Decaestecker C, Debeir O, Spiegl-Kreinecker S, Berger W, Lefranc F, Kast RE, Kiss R. Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines. Eur J Cancer 45:2893-905, 2009.
  73. Mathieu V, Pirker C, Martin de Lassalle E, Vernier M, Mijatovic T, DeNeve N, Gaussin JF, Dehoux M, Lefranc F, Berger W, Kiss R. The sodium pumpa alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med, 13: 3960-3972, 2009.
  74. Djedid R, Tomasi O, Haidara A, Rynkowski M, Lefranc F. Traitement des glioblastomes à l’aube de 2010. Rev Med Bruxelles 30:496-505, 2009.
  75. Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F. Galectins and gliomas. Brain Pathol 20 :17-27, 2009.
  76. Fortin S, Le Mercier M, Camby I, Spiegl-Kreinecker S, Berger W, Lefranc F, Kiss R. Galectin-1 is implicated in the PKC-epsilon / vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol 20:39-49, 2010.
  77. Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, Bikfalvi A, Kiss R, Castronovo V, Bellahcène A. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 126:1797-805, 2010.
  78. Lamoral-Theys D, Le Mercier M, Le Calvé B, Rynkowski MA, Bruyère C, Decaestecker C, Haibe-Kains B, Bontempi G, Dubois J, Lefranc F, Kiss R. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia.12:69-79, 201

 

PARTICIPATIONS A DES LIVRES OU A DES CHAPITRES DE LIVRES

  1. Lefranc F. Le polytraumatisé : Phase précoce de la prise en charge. Imp. : M. Jedwab (tirage à 1000 exemplaires), Bruxelles, 2000.
  2. Brotchi J, Lefranc F. Tumeurs médullaires. Chapitre 15. Neuro-Oncologie. Collection « Traités de Neurologie », Doin éditeurs, 2001.
  3. Lefranc F, Le Mercier M, Mathieu V, Kiss R. Galectin-1, cancer cell migration, angiogenesis, and chemoresistance. Dans : Galectins (Klyosov AA, Witczak ZJ, Platt D ; eds). John Wiley & Sons, Inc., pp.157-191, 2008.
  4. Lefranc F, Djedid R, Bruneau M, Brotchi J. Current management of intramedullary spinal cord tumors. Essential Practice of Neurosurgery. Ed in chief: Kazadi Kalangu, 2010.
  5. Lefranc F, Bruneau M, Brotchi J. Current management of parasagittal meningiomas. Essential Practice of Neurosurgery. Ed in chief: Kazadi Kalangu, 2010.
  6. Bruneau M, Lefranc F, Balériaux D, Brotchi J. Intradural extra and intramedullary spinal cord tumors. Chapter 25 Part 5. Principles of Neurosurgery. Ellenbogen-Abdulrauf. 2010.

 

 

Go to top